Pune, India -- (SBWire) -- 03/06/2018 --Heart failure occurs when the heart cannot pump enough blood and oxygen to support the organs. Coronary artery disease is the one of the main cause which damages the heart muscle that results in heart failure. Some of the other common causes are high blood pressure, and diabetes. The continuous increase in the number of heart failure cases has massively pushed the demand for the heart transplantation procedures.
The Global Heart Transplant Market is expected to grow at a CAGR of 11.2% during the forecast period of 2017-2023.
It has definitely had an impact in the revenues generated through the transplantation treatments which are also considered as a gold standard treatment for advanced heart failure. There are many factors which are responsible for the development of body condition that may lead to heart failures; such as cough- especially at night, poor exercise tolerance, shortness of breath, fatigue, and fluid retention among others.
More than 3,000 people are on the waiting list for the Heart transplant on any given day. However, the number of heart donors is only 2,200 every year. There is a huge gap between the demand of the transplant procedures and the supply for the same. Chances of getting a matching donor and successful heart transplant are very slim for any patient. In this scenario, artificial heart transplant is the best possible chance for the patients for their survival. At this moment, there is only one FDA approved total artificial heart in the market which is manufactured by Syncardia Systems LLC.
Artificial heart transplant has emerged as a boon for the people in need for the heart transplant. It has created a hope for the patients who are desperately waiting for the heart transplant. Syncardia Systems Has played a humongous part in this revolutionary change in the treatment options for this severely critical procedure of heart transplant. Unfortunately, this procedure is currently being used less than 50 times per year as a bridge to heart transplant.
Get a Brochure of This Report @ https://www.marketresearchfuture.com/sample_request/1836 .
Global Heart Transplant Market: Competitive Analysis
Global heart transplant market is a continuously developing market, and there are number of device manufacturers who are involved in the manufacturing and development of the Ventricular access devices and also the total artificial heart. Some of these companies include SynCardia Systems, LLC, HeartWare International Inc., Apaxis Medical, Inc., Calon Cardio, Optum Inc., Thoratec Corporation, CardiacAssist Inc., CARMAT, TransMedics, Inc., ABIOMED, Jarvik Heart and others.
Syncardia System LLC. Is the only company which has received approval from FDA for its Total Artificial Heart. According to the company, "Companion 2" (C2) hospital driver supports patients from implant of the SynCardia temporary Total Artificial Heart. This driver can be replaced with the "Freedom" portable Driver once the patient condition becomes clinically stable. Syncardia currently dominates this segment as there is no competition for their product in the market.
Apart from that, there are number of Ventricular Access devices available in the market. Heartmate Series is an intermediate-to-chronic left ventricular assist device developed by Thoratec Corporation. The company claims that, HeartMate II was developed with the goal of providing up to 10 years of circulatory support for a broad range of advanced heart failure patients. There are few other VAD systems developed by Thoratec Corporation such as PVAD, I VAD pump, and CentriMag.
HVAD pump, developed by HeartWare International Inc is a miniaturized, centrifugal pump capable of delivering up to 10 liters/minute of blood flow from the heart to the rest of the body. The HeartWare VAS is in clinical trials for both bridge to transplantation and destination therapy.
Grab Attractive Discount @ https://www.marketresearchfuture.com/check-discount/1836 .
Jarvik 2000 Heart System is a held in hand system developed by Jarvik Heart. It is a pump, about the size of a C battery. The Jarvik 2000 augments the weakened heart's blood output to help restore a normal blood flow throughout the body.
…Continued
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Heart Transplant Market 2018 by Analyzing the Performance of Various Competitors 2023
Heart Transplant Market provide a detailed analysis, mainly based on Value Chain analysis, Porter’s Five Forces, Price analysis, and Supply Chain analysis etc.